Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Bavarian Nordic experienced an unusually-high trading volume on Tuesday — about 21,280 shares traded, a 730% increase from the prior session, with the stock trading near $9.95.
• Recent fundamentals show a quarterly EPS of -$0.20 and revenue of $226.16 million; the company has a $2.37 billion market cap, a P/E of 11.31, and analysts expect about 0.67 EPS for the current fiscal year.
• Bavarian Nordic is a fully integrated biotech focused on vaccines and immunotherapies, with commercial products including Jynneos (Imvamune/Imvanex), Rabipur, and Encepur.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 21,280 shares changed hands during trading, an increase of 730% from the previous session's volume of 2,564 shares.The stock last traded at $9.9496 and had previously closed at $9.9360.

Bavarian Nordic Stock Performance

The firm has a fifty day simple moving average of $9.94 and a 200-day simple moving average of $10.44. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of 11.31 and a beta of 1.27.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 22.20% and a return on equity of 11.44%. The business had revenue of $226.16 million for the quarter. Analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.